SCHEMBL6457986

SCHEMBL6457986

NC(=O)c1cc(Cl)nc2ccccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.65
HTT P42858 2/20 0.63
USP2 O75604 1/20 0.63
MAPT P10636 7/20 0.59
ALDH1A1 P00352 6/20 0.59
POLB P06746 1/20 0.59
NCOA1 Q15788 1/20 0.59
NCOA3 Q9Y6Q9 1/20 0.59
GAA P10253 3/20 0.56
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C19 P33261 1/20 0.56
AHR P35869 1/20 0.53
HPGD P15428 2/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL57542 0.86 KDM4E (0.69) KDM4EHTTUSP2MAPTALDH1A1
SCHEMBL1613027 0.84 KDM4E (0.67) KDM4EHTTUSP2MAPTALDH1A1
SCHEMBL11506441 0.84 KDM4E (0.67) KDM4EHTTUSP2MAPTALDH1A1
Hydrochloric Acid SCHEMBL31715997 0.84 KDM4E (0.67) KDM4EHTTUSP2MAPTALDH1A1
SCHEMBL13209738 0.83 KDM4E (0.69) KDM4EHTTUSP2MAPTALDH1A1
SCHEMBL27388864 0.81 MAPT (0.63) KDM4EHTTUSP2MAPTALDH1A1
SCHEMBL9574610 0.81 NCOA1 (0.60) NCOA1NCOA3
SCHEMBL28691005 0.81 NCOA1 (0.60) KDM4EHTTPOLBNCOA1NCOA3
SCHEMBL5202032 0.81 NCOA1 (0.65) KDM4EHTTALDH1A1POLBNCOA1
SCHEMBL5781546 0.80 KDM4E (0.61) KDM4EHTTUSP2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110590660-A Quinoline carboxamide compound, preparation method thereof and application of quinoline carboxamide compound in resisting enterovirus 71 武汉大学 2019-12-20 CN claimed
CN-110590660-B Quinoline carboxamide compound, preparation method thereof and application of quinoline carboxamide compound in resisting enterovirus 71 武汉大学 2021-02-19 CN disclosed
CN-110590660-B Quinoline carboxamide compound, preparation method thereof and application of quinoline carboxamide compound in resisting enterovirus 71 武汉大学 2021-02-19 CN disclosed
CN-110590660-A Quinoline carboxamide compound, preparation method thereof and application of quinoline carboxamide compound in resisting enterovirus 71 武汉大学 2019-12-20 CN disclosed
CN-110590660-A Quinoline carboxamide compound, preparation method thereof and application of quinoline carboxamide compound in resisting enterovirus 71 武汉大学 2019-12-20 CN disclosed
WO-2007008657-A2 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-18 WO disclosed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed
CN-1067684-C Imidazo [1,5-1] quinolines for treatment of anxiety and sleep disorders PHAMACIA UPJOHN CO (US) 2001-06-27 CN disclosed
CN-1135753-A Imidazo [1, 5-a ] quinolines for the treatment of anxiety and sleep disorders UPJOHN CO (US) 1996-11-13 CN disclosed
EP-0123146-B1 COMPOUND WITH ANTIINFLAMMATORY ACTIVITY, PROCESS FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREFROM CHIESI FARMACEUTICI S.p.A. (IT) 1990-05-23 EP disclosed
US-4839366-A ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC CHIESI FARMACEUTICI S.P.A. (IT) 1989-06-13 US disclosed
US-4767698-A PHOTOSTABILITY, HEAT RESISTANCE AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) 1988-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 KDM4E 1190/4885HTT 500/4885USP2 3448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.